ANI Pharmaceuticals’ Acquisition of Alimera Sciences Bolsters Buy Rating and $94 Target Price
TipRanks (Tue, 17-Sep 6:15 AM ET)
ANI Pharmaceuticals completes purchase of Alimera Sciences
Seeking Alpha News (Mon, 16-Sep 9:04 AM ET)
ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences
Globe Newswire (Mon, 16-Sep 8:53 AM ET)
ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Sciences
Globe Newswire (Mon, 16-Sep 6:50 AM ET)
Deals this week: Qualcomm, Squarespace, Adnoc, General Mills and more
Seeking Alpha News (Sat, 14-Sep 3:44 PM ET)
Globe Newswire (Fri, 13-Sep 6:50 AM ET)
ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger
Globe Newswire (Wed, 11-Sep 6:50 AM ET)
ANI Pharmaceuticals Provides Update on Closing of Acquisition of Alimera Sciences
Globe Newswire (Tue, 10-Sep 2:09 PM ET)
Alimera Sciences Takes Legal Action Against ANI Pharmaceuticals to Enforce Merger Agreement
Business Wire (Tue, 10-Sep 9:00 AM ET)
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
Ani Pharmaceuticals trades on the NASDAQ stock market under the symbol ANIP.
As of September 18, 2024, ANIP stock price climbed to $61.05 with 357,342 million shares trading.
ANIP has a beta of 0.54, meaning it tends to be less sensitive to market movements. ANIP has a correlation of 0.03 to the broad based SPY ETF.
ANIP has a market cap of $1.28 billion. This is considered a Small Cap stock.
Last quarter Ani Pharmaceuticals reported $138 million in Revenue and $1.02 earnings per share. This beat revenue expectation by $9 million and exceeded earnings estimates by $.08.
In the last 3 years, ANIP stock traded as high as $70.81 and as low as $22.31.
The top ETF exchange traded funds that ANIP belongs to (by Net Assets): IJR, VTI, IWM, VXF, IJT.
ANIP has underperformed the market in the last year with a price return of -2.1% while the SPY ETF gained +27.8%. ANIP has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -1.2% and -3.1%, respectively, while the SPY returned +2.9% and +1.7%, respectively.
ANIP support price is $58.37 and resistance is $61.75 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANIP stock will trade within this expected range on the day.